Sci-Thurs AM: YIS-05: Accuracy of Patient-Specific Dosimetry for Clinical Use in Targeted Radionuclide Therapy

2009 ◽  
Vol 36 (9Part3) ◽  
pp. 4315-4316
Author(s):  
J Grimes ◽  
S Shcherbinin ◽  
A Celler ◽  
B Birkenfeld ◽  
MH Listewnik ◽  
...  
Keyword(s):  
Radionuclide Therapy ◽  
Patient Specific ◽  
Clinical Use ◽  
Targeted Radionuclide Therapy

SU-E-T-256: Optimizing the Combination of Targeted Radionuclide Therapy Agents Using a Multi-Scale Patient-Specific Monte Carlo Dosimetry Platform

2014 ◽  
Vol 41 (6Part15) ◽  
pp. 282-282
Author(s):  
A Besemer ◽  
B Titz ◽  
J Grudzinski ◽  
J Weichert ◽  
L Hall ◽  
...  
Keyword(s):  
Monte Carlo ◽  
Radionuclide Therapy ◽  
Patient Specific ◽  
Targeted Radionuclide Therapy ◽  
Multi Scale

Radiolanthanides in endoradiotherapy: an overview

2007 ◽  
Vol 95 (6) ◽  
Author(s):  
Frank Rösch
Keyword(s):  
Radionuclide Therapy ◽  
Molecular Level ◽  
Interdisciplinary Approach ◽  
Clinical Use ◽  
Targeted Radionuclide Therapy ◽  
Nuclear Decay ◽  
Decay Products ◽  
Disease Site ◽  
Decay Parameters ◽  
Targeting Vector

Endoradiotherapy (targeted radionuclide therapy) is a systemic approach, involving a radiolabeled targeting vector with a well characterized biochemical strategy to selectively deliver a cytotoxic level of radiation to a disease site on a cellular/molecular level. The group of radiolanthanides has been considered both for imaging and therapy over many years. Some radiolanthanides have been and are increasingly applied for therapeutic purposes.However, the clinical use of endoradiotherapeuticals containing radiolanthanides requires a complex and interdisciplinary approach. It involves, among other factors, the choice of the most suitable lanthanide radionuclide (in terms of nuclear decay parameters such as type and energy of the particles emitted, half-life, decay products

scholarly journals Impact of PET and MRI threshold-based tumor volume segmentation on patient-specific targeted radionuclide therapy dosimetry using CLR1404

2017 ◽  
Vol 62 (15) ◽  
pp. 6008-6025 ◽  
Author(s):  
Abigail E Besemer ◽  
Benjamin Titz ◽  
Joseph J Grudzinski ◽  
Jamey P Weichert ◽  
John S Kuo ◽  
...  
Keyword(s):  
Radionuclide Therapy ◽  
Tumor Volume ◽  
Patient Specific ◽  
Targeted Radionuclide Therapy ◽  
Volume Segmentation

scholarly journals Update on Preclinical Development and Clinical Translation of Cholecystokinin-2 Receptor Targeting Radiopharmaceuticals

Cancers ◽  
2021 ◽  
Vol 13 (22) ◽  
pp. 5776
Author(s):  
Elisabeth von Guggenberg ◽  
Petra Kolenc ◽  
Christof Rottenburger ◽  
Renata Mikołajczak ◽  
Alicja Hubalewska-Dydejczyk
Keyword(s):  
Clinical Trials ◽  
Radionuclide Therapy ◽  
Medullary Thyroid Cancer ◽  
Clinical Results ◽  
Targeted Imaging ◽  
Clinical Use ◽  
Targeted Radionuclide Therapy ◽  
Imaging Studies ◽  
Preclinical Development ◽  
Medullary Thyroid

The cholecystokinin-2 receptor (CCK2R) has been a target of interest for molecular imaging and targeted radionuclide therapy for two decades. However, so far CCK2R targeted imaging and therapy has not been introduced in clinical practice. Within this review the recent radiopharmaceutical development of CCK2R targeting compounds and the ongoing clinical trials are presented. Currently, new gastrin derivatives as well as nonpeptidic substances are being developed to improve the properties for clinical use. A team of specialists from the field of radiopharmacy and nuclear medicine reviewed the available literature and summarized their own experiences in the development and clinical testing of CCK2R targeting radiopharmaceuticals. The recent clinical trials with novel radiolabeled minigastrin analogs demonstrate the potential for both applications, imaging as well as targeted radiotherapy, and reinforce the clinical applicability within a theranostic concept. The intense efforts in optimizing CCK2R targeting radiopharmaceuticals has led to new substances for clinical use, as shown in first imaging studies in patients with advanced medullary thyroid cancer. The first clinical results suggest that the wider clinical implication of CCK2R-targeted radiopharmaceuticals is reasonable.

scholarly journals Patient-Specific Dosimetry Using Pretherapy [124I]m-iodobenzylguanidine ([124I]mIBG) Dynamic PET/CT Imaging Before [131I]mIBG Targeted Radionuclide Therapy for Neuroblastoma

2014 ◽  
Vol 17 (2) ◽  
pp. 284-294 ◽  
Author(s):  
Shih-ying Huang ◽  
Wesley E. Bolch ◽  
Choonsik Lee ◽  
Henry F. Van Brocklin ◽  
Miguel H. Pampaloni ◽  
...  
Keyword(s):  
Radionuclide Therapy ◽  
Ct Imaging ◽  
Patient Specific ◽  
Targeted Radionuclide Therapy ◽  
Dynamic Pet ◽  
Pet Ct ◽  
131I Mibg

Organs dosimetry in targeted radionuclide therapy

2021 ◽  
pp. 109668
Author(s):  
Meshari Alnaaimi ◽  
Abdelmoneim Sulieman ◽  
Mohammed Alkhorayef ◽  
Hasan Salah ◽  
Musa Alduaij ◽  
...  
Keyword(s):  
Radionuclide Therapy ◽  
Targeted Radionuclide Therapy
Sign in / Sign up

Export Citation Format

Share Document